Table 2.
Data input for benefit-harm assessment
| Patient experiences with treatment outcomes over time for the two randomized treatment groups
| ||
|---|---|---|
| Implant therapy group Number of patients, n/N (%) |
Systemic therapy group Number of patients, n/N (%) |
|
| Visual acuity of the better-seeing eye remained at worse than 20/40 or decreased to worse than 20/40 at each time point | ||
| 6 months | 33/121 (27%) | 28/115 (24%) |
| 12 months | 37/119 (31%) | 24/115 (21%) |
| 18 months | 29/114 (25%) | 21/117 (18%) |
| 24 months | 33/118 (28%) | 24/114 (21%) |
| Number of patients who ever had the event(s) at each time point | ||
| Incident glaucoma | ||
| 6 months | 0/116 (0%) | 0/115 (0%) |
| 12 months | 1/116 (1%) | 0/115 (0%) |
| 18 months | 1/116 (1%) | 0/114 (0%) |
| 24 months | 27/116 (23%) | 7/114 (6%) |
| Requiring cataract surgery | ||
| 6 months | 23/124 (19%) | 6/121 (5%) |
| 12 months | 43/124 (35%) | 16/120 (13%) |
| 18 months | 65/123 (53%) | 25/120 (21%) |
| 24 months | 74/121 (61%) | 30/119 (25%) |
| Requiring glaucoma surgery | ||
| 6 months | 8/124 (6%) | 3/121 (2%) |
| 12 months | 21/124 (17%) | 3/120 (3%) |
| 18 months | 33/123 (27%) | 4/120 (3%) |
| 24 months | 40/121 (33%) | 8/119 (7%) |
| Incident cataracts | ||
| 6 months | 11/24 (46%) | 5/21 (24%) |
| 12 months | 22/24 (92%) | 8/21 (38%) |
| 18 months | 22/24 (92%) | 8/21 (38%) |
| 24 months | 23/24 (96%) | 10/21 (48%) |
| Prescription-requiring hypertension | ||
| 6 months | 2/124 (2%) | 3/121 (2%) |
| 12 months | 4/124 (3%) | 4/120 (3%) |
| 18 months | 4/123 (3%) | 5/120 (4%) |
| 24 months | 5/121 (4%) | 9/119 (8%) |
| Prescription-requiring hyperlipidemia | ||
| 6 months | 1/124 (1%) | 3/121 (2%) |
| 12 months | 2/124 (2%) | 3/120 (3%) |
| 18 months | 3/123 (2%) | 7/120 (6%) |
| 24 months | 3/121 (2%) | 8/119 (7%) |
| Prescription-requiring infections | ||
| 6 months | 25/124 (20%) | 27/121 (22%) |
| 12 months | 32/124 (26%) | 38/120 (32%) |
| 18 months | 38/123 (31%) | 52/120 (43%) |
| 24 months | 45/122 (37%) | 57/119 (48%) |
| Weights assigned in the main and sensitivity analyses | |||
|---|---|---|---|
|
| |||
| Outcome | Main analysis (weights obtained from the patient preferences survey)* |
Sensitivity analysis one |
Sensitivity analysis two |
| Visual acuity of the better-seeing eyes remained at worse than 20/40 or decreased to worse than 20/40 | 0.8 | 1.0 | 1.0 |
| Incident glaucoma | 0.7 | 1.0 | 0.5 |
| Requiring cataract surgery | 0.6 | 1.0 | 0.5 |
| Requiring glaucoma surgery | 0.6 | 1.0 | 0.5 |
| Incident cataracts | 0.3 | 0.5 | 0.25 |
| Prescription-requiring hypertension | 0.3 | 0.5 | 0.25 |
| Prescription-requiring hyperlipidemia | 0.3 | 0.5 | 0.25 |
| Prescription-requiring infections | 0.2 | 0.5 | 0.25 |
*
The preference estimates are on a −5 to 5 scale. We rescaled the median of the preference estimates to a 0 to1 scale. For example, the median of the preference estimate of incident glaucoma is 2, and the weights we assigned in analysis is 2-(−5)/10, or 0.7.